China SXT Pharmaceuticals, Inc.
SXTC
$1.50
$0.021.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.74% | -1.99% | 6.78% | 1.97% | -2.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.74% | -1.99% | 6.78% | 1.97% | -2.18% |
| Cost of Revenue | -0.06% | 13.83% | 31.54% | 6.44% | -11.07% |
| Gross Profit | -33.68% | -34.88% | -35.94% | -9.21% | 29.99% |
| SG&A Expenses | 15.17% | -118.95% | -144.16% | -118.07% | -53.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.96% | -101.97% | -131.66% | -103.48% | -44.39% |
| Operating Income | -28.11% | 125.33% | 149.18% | 124.19% | 60.21% |
| Income Before Tax | -6.62% | 114.46% | 140.99% | 113.43% | 47.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.62% | 114.46% | 140.99% | 113.43% | 47.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.62% | 114.46% | 140.99% | 113.43% | 47.79% |
| EBIT | -28.11% | 125.33% | 149.18% | 124.19% | 60.21% |
| EBITDA | -37.54% | 127.74% | 151.37% | 126.88% | 62.28% |
| EPS Basic | 97.31% | 110.83% | 117.22% | 83.70% | 43.82% |
| Normalized Basic EPS | 97.24% | 111.94% | 118.89% | 84.50% | 43.35% |
| EPS Diluted | 97.31% | 110.83% | 117.22% | 83.70% | 43.82% |
| Normalized Diluted EPS | 97.24% | 111.94% | 118.89% | 84.50% | 43.35% |
| Average Basic Shares Outstanding | 1,212.40% | 920.59% | 378.23% | 322.34% | 224.70% |
| Average Diluted Shares Outstanding | 1,212.40% | 920.59% | 378.23% | 322.34% | 224.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |